738 related articles for article (PubMed ID: 11379859)
1. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients.
Navarro JF; Mora C; Jiménez A; Torres A; Macía M; García J
Am J Kidney Dis; 1999 Jul; 34(1):43-8. PubMed ID: 10401014
[TBL] [Abstract][Full Text] [Related]
4. Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?
Wei M; Esbaei K; Bargman JM; Oreopoulos DG
Int Urol Nephrol; 2006; 38(2):317-22. PubMed ID: 16868704
[TBL] [Abstract][Full Text] [Related]
5. Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?
Navarro JF; Macía ML; Gallego E; Méndez ML; Chahín J; García-Nieto V; García JJ
Scand J Urol Nephrol; 1997 Jun; 31(3):275-80. PubMed ID: 9249893
[TBL] [Abstract][Full Text] [Related]
6. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
9. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptiometry.
Pasadakis P; Thodis E; Mourvati E; Euthimiadou A; Margaritis D; Manavis J; Vargemezis V
Adv Perit Dial; 1996; 12():245-9. PubMed ID: 8865913
[TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
13. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis.
Dimkovic NB; Bargman J; Vas S; Oreopoulos DG
Perit Dial Int; 2002; 22(2):204-10. PubMed ID: 11990405
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients.
Ohya M; Negi S; Sakaguchi T; Koiwa F; Ando R; Komatsu Y; Shinoda T; Inaguma D; Joki N; Yamaka T; Ikeda M; Shigematsu T
J Clin Endocrinol Metab; 2014 Oct; 99(10):3873-8. PubMed ID: 24937533
[TBL] [Abstract][Full Text] [Related]
15. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
[TBL] [Abstract][Full Text] [Related]
16. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency.
Rude RK; Oldham SB; Singer FR
Clin Endocrinol (Oxf); 1976 May; 5(3):209-24. PubMed ID: 182417
[TBL] [Abstract][Full Text] [Related]
17. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.
Qi Q; Monier-Faugere MC; Geng Z; Malluche HH
Am J Kidney Dis; 1995 Oct; 26(4):622-31. PubMed ID: 7573017
[TBL] [Abstract][Full Text] [Related]
19. Differences in calcium kinetic pattern between CAPD and HD patients.
Kurz P; Tsobanelis T; Roth P; Werner E; Ewald U; Grützmacher P; Schoeppe W; Vlachojannis J
Clin Nephrol; 1995 Oct; 44(4):255-61. PubMed ID: 8575126
[TBL] [Abstract][Full Text] [Related]
20. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
